Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stuart Edwards: Tale of a Serial Entrepreneur

This article was originally published in Start Up

Executive Summary

Few individuals can successfully combine an inventor's creativity with an entrepreneur's business acumen to launch a device start-up company. Doing that nearly a dozen times, as Stuart Edwards has, is quite a feat, particularly in today's hostile environment for device company creation. Edwards has a unique formula, relying on a common technology base (radio frequency or RF energy) which he applies to untapped markets, such as sleep and gastrointestinal disorders. Critics of his unorthodox approach claim Edwards fails to maximize value, creating separate companies rather than building a single company with greater critical mass. But Edwards has yet to have a company fail and investors are returning for more.

Related Content

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

MT037076

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel